Who is sponsoring NCT03137758?

NCT03137758 is sponsored by Pellficure Pharmaceuticals, Inc.

What drugs are being tested in NCT03137758?

Interventions in NCT03137758: PCUR - 101.

What condition does NCT03137758 study?

NCT03137758 studies Metastatic Castration-Resistant Prostate Cancer.

Is NCT03137758 still recruiting?

NCT03137758 is currently terminated. Last updated 9 March 2020.

Last reviewed 2020-03-09 · How we verify

NCT03137758

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Terminated Phase 1 Last updated 9 March 2020

What this trial tests

Phase 1 trial testing PCUR - 101 in Metastatic Castration-Resistant Prostate Cancer in 12 participants. Terminated before completion.

Timeline

24 July 2017

Primary endpoint
3 April 2019

17 September 2019

Quick facts

Lead sponsor	Pellficure Pharmaceuticals, Inc
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	24 July 2017
Primary completion	3 April 2019
Estimated completion	17 September 2019
Sites	3 locations across United States

Drugs / interventions tested

PCUR - 101 — full drug profile →

Conditions studied

Metastatic Castration-Resistant Prostate Cancer — all drugs for Metastatic Castration-Resistant Prostate Cancer →

Sponsor

Pellficure Pharmaceuticals, Inc — full company profile →

Who can join

18 and older, male only, with Metastatic Castration-Resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of PCUR-101 in combination with androgen suppression therapy in the patients with metastatic CRPC

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Plumbagin-Loaded Nanoemulsion Drug Delivery Formulation and Evaluation of Antiproliferative Effect on Prostate Cancer Cells.
Chrastina A, Baron VT, Abedinpour P, Rondeau G, et al · · 2018 · cited 29× · PMID 30534567 · DOI 10.1155/2018/9035452
Synergistic Anticancer Activity of Plumbagin and Xanthohumol Combination on Pancreatic Cancer Models.
Palanisamy R, Indrajith Kahingalage N, Archibald D, Casari I, et al · · 2024 · cited 8× · PMID 38397018 · DOI 10.3390/ijms25042340
Propylene Glycol Caprylate-Based Nanoemulsion Formulation of Plumbagin: Development and Characterization of Anticancer Activity.
Chrastina A, Welsh J, Borgström P, Baron VT. · · 2022 · cited 6× · PMID 35047632 · DOI 10.1155/2022/3549061

Verify or expand the search:

Other recruiting trials for Metastatic Castration-Resistant Prostate Cancer

Currently open trials in the same condition.

NCT07287150 — A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer · Phase 2 · recruiting
NCT06842498 — A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Phase 2 · recruiting
NCT07344311 — A Phase I Trial of A-CAR032 in Participants With mCRPC · Phase 1 · recruiting
NCT07339267 — A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer · Phase 1 · recruiting
NCT07005154 — A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer · Phase 2 · recruiting

Other Pellficure Pharmaceuticals, Inc trials

Trials by the same sponsor.

NCT04677855 — Study of PCUR-101 in Combination With ADT in Patients With mCRPC · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03137758 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pellficure Pharmaceuticals, Inc
Last refreshed: 9 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03137758.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing